Baader Bank set a CHF 90 price objective on Novartis AG (VTX:NOVN) in a report released on Tuesday morning. The firm currently has a buy rating on the stock.
A number of other equities research analysts also recently issued reports on NOVN. Goldman Sachs Group, Inc. (The) set a CHF 80 price target on shares of Novartis AG and gave the stock a neutral rating in a report on Tuesday, October 17th. Morgan Stanley set a CHF 88 price target on shares of Novartis AG and gave the stock a buy rating in a report on Wednesday, July 26th. Berenberg Bank set a CHF 85 price target on shares of Novartis AG and gave the stock a neutral rating in a report on Friday, July 14th. Deutsche Bank AG set a CHF 80 price target on shares of Novartis AG and gave the stock a neutral rating in a report on Friday, July 7th. Finally, Sanford C. Bernstein set a CHF 94 price target on shares of Novartis AG and gave the stock a buy rating in a report on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of CHF 85.90.
Shares of Novartis AG (NOVN) opened at 81.30 on Tuesday. Novartis AG has a 52 week low of CHK 67.40 and a 52 week high of CHK 85.40. The firm has a 50-day moving average of CHK 83.19 and a 200 day moving average of CHK 80.22. The firm has a market cap of CHK 190.48 billion and a PE ratio of 29.68.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/baader-bank-analysts-give-novartis-ag-novn-a-chf-90-price-target.html.
Novartis AG Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.